OR WAIT null SECS
New California plant expected to streamline medicine production.
Genentech, a biotechnology company and member of the Roche Group, is adding a new biologics manufacturing facility to its existing campus in Oceanside, Calif. With the anticipated investment totaling $450 million, the new site will reportedly be employing digital technologies to move medicines from production to patients, both at a faster rate and more sustainably. The Oceanside campus was selected due to its proximity to a pool of biotech talent in the area.
Once it becomes operational in early 2025, the site will be the first location in the company’s global manufacturing network designed specifically for commercial production of biologics for smaller patient populations, including rare diseases and personalized medicines.
“… We remain committed to our home state of California and continue to invest in new ways to bring medicines to patients quicker and more sustainably,” notes Alexander Hardy, CEO of Genentech.